Jan 11, 2021 / 01:20PM GMT
David James Adlington - JPMorgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research
Good morning, good afternoon, everybody. This is David Adlington from the JPMorgan med tech team in Europe. It's my pleasure this morning to start off with Stephan Sturm, CEO of Fresenius SE.
Stephan is going to make some, I think, brief introductory comments, and then we're going to head into Q&A. Thanks for joining us today, Stephan, and over to you for those comments.
Stephan Sturm - Fresenius SE & Co. KGaA - CEO, President & Chairman of Management Board - Fresenius Management SE
Thank you, David. Thank you. Good morning, everyone. Your interest in Fresenius is appreciated, as always. Happy new year, even though 2021 has already started.
Very briefly, we have had a different and a difficult 2020 by normal Fresenius standards. We had a good Q1 but had a trough in the second quarter where, in particular, the lack of elective surgery at our hospital businesses were felt. We were saying at the time that we
Fresenius SE & Co KGaA at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers